Myriad Genetics, Inc.
MYGNHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeMyriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. With a market capitalization of $556.7M, it sits in small-cap territory. It offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.
Market Cap
$556.7M
Beta
1.64
P/E (TTM)
—
P/E (Fwd)
-9.89
EPS (TTM)
$-1.22
EPS (Fwd)
$-0.59
ROE
-32.5%
ROA
-8.6%
Cash
$115.2M
Total Debt
$210.5M
Free CF
$18.2M
52W Change
-28.1%
Annual Financials
Cash vs Debt
Where MYGN stands vs its 150-day and 200-day moving averages
As of the October 16, 2026 close, MYGN finished 0.91% below its 150-day moving average ($4.39) and 6.25% below its 200-day moving average ($4.64). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MYGN overbought or oversold?
At the October 16, 2026 close, MYGN's RSI(14) was 54.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Myriad Genetics, Inc. carries $210.5M in total debt against $115.2M in cash reserves — debt is roughly 1.8x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $18.2M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -32.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $678.4M (2022) to $824.5M (2025), reflecting a 22% increase over the period.
A beta of 1.64 means MYGN is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Myriad Genetics, Inc.'s trajectory.